Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19.
Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19.
复制标题
DOI：
10.1111/cts.12860
复制
发表时间：
2020-11
期刊：
影响因子：
--
通讯作者：
Scaglione F
中科院分区：
文献类型：
--
作者：
Lauriola M;Pani A;Ippoliti G;Mortara A;Milighetti S;Mazen M;Perseghin G;Pastori D;Grosso P;Scaglione F
Conflicting evidence regarding the use of hydroxychloroquine (HCQ) and azithromycin for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection do exist. We performed a retrospective single‐center cohort study including 377 consecutive patients admitted for pneumonia related to coronavirus disease 2019 (COVID‐19). Of these, 297 were in combination treatment, 17 were on HCQ alone, and 63 did not receive either of these 2 drugs because of contraindications. The primary end point was in‐hospital death. Mean age was 71.8 ± 13.4 years and 34.2% were women. We recorded 146 deaths: 35 in no treatment, 7 in HCQ treatment group, and 102 in HCQ + azithromycin treatment group (log rank test for Kaplan–Meier curve P < 0.001). At multivariable Cox proportional hazard regression analysis, age (hazard ratio (HR) 1.057, 95% confidence interval (CI) 1.035–1.079, P < 0.001), mechanical ventilation/continuous positive airway pressure (HR 2.726, 95% CI 1.823–4.074, P < 0.001), and C reactive protein above the median (HR 2.191, 95% CI 1.479–3.246, P < 0.001) were directly associated with death, whereas use of HCQ + azithromycin (vs. no treatment; HR 0.265, 95% CI 0.171–0.412, P < 0.001) was inversely associated. In this study, we found a reduced in‐hospital mortality in patients treated with a combination of HCQ and azithromycin after adjustment for comorbidities. A large randomized trial is necessary to confirm these findings.
登录
查看更多内容
影响因子：
158.5
作者：
Cao, B.;Wang, Y.;Wang, C.
通讯作者：
Wang, C.
影响因子：
11.8
作者：
Perinel, Sophie;Launay, Manon;Delavenne, Xavier
通讯作者：
Delavenne, Xavier
DOI：
10.1016/j.ijantimicag.2020.105949
发表时间：
2020-07-01
影响因子：
10.8
作者：
Gautret, Philippe;Lagier, Jean-Christophe;Raoult, Didier
通讯作者：
Raoult, Didier
影响因子：
6.7
作者：
Al-Kofahi, Mahmoud;Jacobson, Pamala;Nicol, Melanie R.
通讯作者：
Nicol, Melanie R.
2019年严重冠状病毒病患者（COVID-19）患者的电解质失衡。
影响因子：
2.2
作者：
Lippi G;South AM;Henry BM
通讯作者：
Henry BM